Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CORV

Correvio Pharma (CORV) Stock Price, News & Analysis

About Correvio Pharma Stock (NASDAQ:CORV)

Advanced Chart

Key Stats

Today's Range
$0.42
$0.42
50-Day Range
$0.39
$0.42
52-Week Range
$0.21
$2.79
Volume
N/A
Average Volume
5.35 million shs
Market Capitalization
$27.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Correvio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its portfolio of marketed brands comprise Aggrastat (tirofiban hydrochloride) for patients with acute coronary syndrome; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. The company also offers ESMOCARD and ESMOCARD LYO, a short acting beta blocker for the treatment of supraventricular tachycardia and control of the ventricular rate in patients with atrial fibrillation; Trevyent, a development stage drug/device combination product for pulmonary arterial hypertension; Xydalba, a treatment for acute bacterial skin and skin structure infections; and Zevtera/Mabelio, a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity. Correvio Pharma Corp. was incorporated in 2018 and is headquartered in Vancouver, Canada.

Receive CORV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Correvio Pharma and its competitors with MarketBeat's FREE daily newsletter.

CORV Stock News Headlines

Corvus Pharmaceuticals announces preclinical dataon soquelitinib
New Rule Hits in July — The Smart Money Already Moved
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
An Overview of Corvus Pharma's Earnings
Atea Pharmaceuticals Advances in HCV Treatment Development
See More Headlines

CORV Stock Analysis - Frequently Asked Questions

Correvio Pharma Corp (NASDAQ:CORV) posted its quarterly earnings data on Monday, March, 30th. The company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.13) by $0.06. The firm earned $11.33 million during the quarter, compared to analysts' expectations of $11.52 million. Correvio Pharma had a negative trailing twelve-month return on equity of 2,128.82% and a negative net margin of 107.81%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Correvio Pharma investors own include Inovio Pharmaceuticals (INO), NightHawk Biosciences (NHWK), SCYNEXIS (SCYX), Acasti Pharma (ACST), Onconova Therapeutics (ONTX), Oncobiologics (OTLK) and Vaxart (VXRT).

Company Calendar

Last Earnings
3/30/2020
Today
6/23/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CORV
CIK
N/A
Fax
N/A
Employees
133
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$35.18 million
Net Margins
-107.81%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$32.63 million
Price / Cash Flow
N/A
Book Value
($0.02) per share
Price / Book
-21.00

Miscellaneous

Free Float
N/A
Market Cap
$27.80 million
Optionable
Optionable
Beta
0.08
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:CORV) was last updated on 6/24/2025 by MarketBeat.com Staff
From Our Partners